Effect of Fish Oil on Adiposity and Atherogenic Factors in Type 2 Diabetic Women
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00371982
: September 4, 2006
Last Update Posted
: September 4, 2006
Assistance Publique - Hôpitaux de Paris
Institut National de la Santé Et de la Recherche Médicale, France
whether the intake of n-3 PUFA has additional effects on insulin sensitivity and adiposity (total fat mass and adipocyte morphology and function) in T2D women.
n-3 PUFA supplementation might influence inflammatory genes expression in the adipose tissue of T2D patients.
Condition or disease
Type 2 Diabetes
Drug: Fish oil (Maxepa)
Thus, the present study was designed to evaluate the effects of n-3 PUFAs dietary supplementation on lipid and glucose homeostasis and to address the impact of this treatment on adiposity and adipose tissue gene expression in T2D women.A total of 27 T2D women (BMI 27-35kg/m², age 40-60 y) were randomly allocated to two months of 3 g/day of either fish oil (1.8 g n-3 PUFA) or placebo (paraffin oil), in a double-blind parallel design.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study:
40 Years to 60 Years (Adult)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Type 2 diabetic postmenopausal women
glycaemia of 7.87-14.0 mmol/l, HbA1c of 7 to 10.5%
plasma triglycerides between 1.72-4.6 mmol/l,
aged between 40 -60,
BMI: 27-40 kg/m2
able to swallow tablets
patients with abnormal renal, hepatic and thyroid functions as determined by physical examination, blood cell count and standard blood biochemical profile
patients with gastrointestinal disorders
patients treated with thiazolidinediones or insulin